Pourazizi, M. , Kabiri, S. and Abtahi-Naeini, B. (2017). Intralesional bevacizumab (Avastin®) as a novel addition to infantile hemangioma management: A medical hypothesis. Journal of Research in Pharmacy Practice, 6(3), 190-191.
MLA
Pourazizi, M. , , Kabiri, S. , and Abtahi-Naeini, B. . "Intralesional bevacizumab (Avastin®) as a novel addition to infantile hemangioma management: A medical hypothesis", Journal of Research in Pharmacy Practice, 6, 3, 2017, 190-191.
HARVARD
Pourazizi, M., Kabiri, S., Abtahi-Naeini, B. (2017). 'Intralesional bevacizumab (Avastin®) as a novel addition to infantile hemangioma management: A medical hypothesis', Journal of Research in Pharmacy Practice, 6(3), pp. 190-191.
CHICAGO
M. Pourazizi , S. Kabiri and B. Abtahi-Naeini, "Intralesional bevacizumab (Avastin®) as a novel addition to infantile hemangioma management: A medical hypothesis," Journal of Research in Pharmacy Practice, 6 3 (2017): 190-191,
VANCOUVER
Pourazizi, M., Kabiri, S., Abtahi-Naeini, B. Intralesional bevacizumab (Avastin®) as a novel addition to infantile hemangioma management: A medical hypothesis. Journal of Research in Pharmacy Practice, 2017; 6(3): 190-191.
)